Chugai Pharmaceutical (OTCMKTS:CHGCY) Shares Gap Down - Time to Sell?

Key Points

• Chugai Pharmaceutical shares gapped down from a previous close of $21.97 to an opening price of $21.28, with a last traded price of $21.97.
• The company reported a quarterly earnings per share (EPS) of $0.20 with revenue of $2.01 billion and has a net margin of 33.08%.
• Analysts are predicting an EPS of 0.74 for Chugai Pharmaceutical for the current year.

Shares of Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (OTCMKTS:CHGCY - Get Free Report) gapped down prior to trading on Friday . The stock had previously closed at $21.97, but opened at $21.28. Chugai Pharmaceutical shares last traded at $21.97, with a volume of 1,827 shares traded.

Chugai Pharmaceutical Trading Down 0.4%

The company has a market cap of $72.04 billion, a PE ratio of 27.71 and a beta of 0.65. The firm's 50-day simple moving average is $23.39 and its two-hundred day simple moving average is $24.63.

Chugai Pharmaceutical (OTCMKTS:CHGCY - Get Free Report) last posted its quarterly earnings data on Thursday, July 24th. The company reported $0.20 EPS for the quarter. The business had revenue of $2.01 billion during the quarter. Chugai Pharmaceutical had a net margin of 33.08% and a return on equity of 20.80%. As a group, analysts predict that Chugai Pharmaceutical Co., Ltd. Unsponsored ADR will post 0.74 EPS for the current year.

About Chugai Pharmaceutical

Chugai Pharmaceutical Co, Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company's products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; Edirol, an Osteoporosis agent; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Bonviva, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.